Antibacterial effects of gum kondagogu reduced/stabilized silver nanoparticles in combination with various antibiotics: a mechanistic approach

Abstract

Gum kondagogu reduced/stabilized silver nanoparticles (GK-AgNPs) were evaluated for their increased antibacterial and antibiofilm activities in combination with various antibiotics (ciprofloxacin, streptomycin and gentamicin) against Gram-positive (Staphylococcus aureus 25923, Staphylococcus aureus 49834) and Gram-negative (Escherichia coli 25922, Pseudomonas aeruginosa 27853) bacteria. The micro-broth dilution assay suggested an enhanced antibacterial activity of GK-AgNPs in combination with ciprofloxacin and aminoglycosides (streptomycin and gentamicin) against tested strains. Though the antibacterial activity of GK-AgNPs was found to increase significantly in the presence of antibiotics, the % enhancement was found to depend on both types of antibiotic and bacterial strain. It was also found that GK-AgNPs (1 µg/mL) in combination with various antibiotics at sub-MIC concentrations could inhibit 70 % of the bacterial biofilm formation as compared to respective controls. The enhanced antibacterial activity was due to the increased production of intracellular reactive oxygen species in bacteria when treated with a combination of GK-AgNPs and streptomycin as compared to individual treatment. The increased oxidative stress led to increased membrane damage as assessed by live/dead assay and higher levels of potassium ion release from the cells treated with both silver nanoparticles and streptomycin. The results suggested that the combination of antibiotics with GK-AgNPs has an enhanced antibacterial action. Further, the GK-AgNPs were found to be biocompatible up to a concentration of 2.5 µg/mL as assessed with MTT assay on HeLa cell line. The results suggest that GK-AgNPs could potentially be used as in vivo antibacterial agent in combination with antibiotics to overcome the problem of antibiotic resistance.